Pharmacokinetic Considerations for Angiogenesis Inhibitors Used to Treat Hepatocellular Carcinoma: An Overview

The authors summarize the pharmacokinetic characteristic of the antigiogenic drugs currently approved for the treatment of HCC, from oral tyrosine kinase inhibitors to monoclonal antibodies.